avb-620
PeptideexperimentalImaging agent
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2015 (NCT02391194)
Timeline
Indications
Mechanism of action
- Matrix metalloproteinase-1INHIBITOR
MMP1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- avb-620
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03113825 | Phase 2 | Jul 5, 2017 | Avelas Biosciences, Inc., Clinipace LTD |
| NCT02391194 | Phase 1 | Apr 1, 2015 | Avelas Biosciences, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Avelas Biosciences, Inc. | For profit | 2 | 2 | 2 | 2015 |
| Clinipace LTD | For profit | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1